Pharming Group N.V. ADR PHAR 深 滬
已收盤 10-03 16:00:00 美东时间
16.14
+0.910
+5.98%
華盛通- 最 高16.29
- 今 開16.13
- 成交量 1.07万股
- 最 低 15.75
- 昨 收 15.23
- 總市值 11.04亿
- 52周最高 17.08
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 7.31
- 委 比 90.76%
- 總股本 6839.31万
- 歷史最高 21.99
- 量 比 0.61
- 振 幅 3.55%
- 歷史最低 6.10
- 每 手 1
- 風險率 1.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jubilant Pharmova to Transfer Unclaimed Shares to IEPF
The latest update is out from Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ). J...
10-05 08:52
Jubilant Pharmova Enhances Shareholder Engagement with New Initiatives
The latest update is out from Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ). J...
10-02 05:54
CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO
Injectable Ibuprofen Approved for Treating Pain & Fever NASHVILLE, Tenn., Oct. 1 , 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, to...
10-01 21:05
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
Pharming Group N.V. announced that the U.S. FDA has accepted its sNDA for leniolisib as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency. The application, granted Priority Review, is based on positive Phase III study data showing improved immune function in young patients. Leniolisib is already approved for APDS in adults and adolescents 12 and olde...
10-01 05:00
Pfizer To Highlight Data Across Its Oncology Portfolio, Including Five Late-Breaking Presentations And Recognition In Presidential Symposium, At ESMO Congress 2025
More than 45 abstracts, including five late-breaking presentations and recognition in Presidential Symposium, showcase impact of approved medicines and potential of next-generation pipeline
09-25 18:47
Jubilant Pharmova Completes USFDA Inspection with No Observations
An announcement from Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) is now avai...
09-21 03:12
Pharming Group promoted to the Euronext AMX® index
Pharming Group N.V. has been promoted to the Euronext AMX (MidCap) index, effective September 22, 2025, reflecting its strong growth momentum. The company, which focuses on rare diseases, aims to enhance visibility and attract investors, supporting its goal of becoming a leading global rare disease company.
09-10 05:00
Sun Pharma’s Halol Facility Faces FDA Compliance Challenges
Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) has provided an updat...
09-09 23:23
Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference
Pharming Group N.V. will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025. Fabrice Chouraqui, CEO, will present on September 8 at 1:30pm EDT. The presentation will be available live and on replay via Pharming’s website. Pharming is a global biopharmaceutical company focused on advancing treatments for rare diseases, with operations spanning over 30 markets worldwide. For further infor...
09-03 06:00
Pharming Group names new finance head
Pharming Group (PHAR) appointed Kenneth Lynard as CFO, effective October 1, 2025. Mr. Lynard is a seasoned finance executive with over 20 years of global leadership experience in the life sciences i...
09-02 16:25
